Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Mustang Bio’s stock leapt more than 400% before settling down, on the news that its gene therapy cured eight infants with “bubble boy” syndrome.
Abbott Laboratories posted a 2% increase in sales for its first quarter this year, topping $7.5 billion worldwide and ahead of expectations.
Mitotech – a biotech specializing in targeting mitochondria – is moving into late stage of clinical development in Dry Eye Disease.
IBM is ending sales of its Watson programs aimed at drug discovery and development over poor financial returns, according to a report from Stat.
The breakthrough tag comes as Genfit gears up to start a phase 3 trial in the indication later in the year.
The drug ACT017 from Acticor targets GPVI, a platelet protein that's critical for blood clot formation but doesn’t affect the regulation of bleeding.
The appointment gives Obsidian a full-time CEO following a period in which Michael Gilman helmed the biotech while also running Arrakis Therapeutics.
Biotech vet Michael Gilman stepped down as Obsidian Therapeutics' CEO and buckled in at Arrakis as the company advances four RNA-targeting drugs.
Talaris Therapeutics raised $100 million to move its cell therapy for kidney transplant patients into phase 3.
Scientists from the Children’s Hospital of Philadelphia and UPenn have used CRISPR gene editing to prevent a lung disease in mice before birth.
Bardy Diagnostics, developers of a remote cardiac monitoring chest patch, raised $35.5 million to help fund its platform and expand its sales force.